tbuckley/cabot-search huggingface dataset:
Desk Job—an app to encourage health and fitness in the workplace and beyond: mobile app user guide
Authors: Charlene M McShane, Daniel MacElhatton
Journal: British Journal of Sports Medicine (2017)

Desk Job.

Health and fitness.

iOS (requires iOS 8.0 or later).

iOS: £0.99.

The ‘Desk Job’ app reminds users to break up their sitting time by setting an alarm to take a break (figure 1). Users can select from a range of times for both sitting (5–120 min) and break (1–60 min) periods. When a break is due, users are prompted to perform stretching or strengthening exercises of a particular body part preselected by the app (eg, ‘stretch the neck’). The app features exercises broadly categorised into different body areas (figure 2). Each exercise is accompanied by an image, a brief description of the purpose and step-by-step instructions on how to complete the …
PP23. MAPPING FOR BRAIN TUMOURS: AN UNDER-UTILISED TOOL?
Authors: Mr Francesco Vergani, Mr Christian Brogna, Mr Ranj Bhangoo, Prof Keyoumars Ashkan
Journal: Neuro-Oncology (2017)

INTRODUCTION: the use of cortical and subcortical intraoperative mapping is an established procedure to maximise the extent of resection in patients with brain tumours close to eloquent areas, while minimising the risk of inducing permanent deficits. Nonetheless, the exact percentage of patients that can benefit from intraoperative mapping remains unknown. AIMS: - to actively and prospectively evaluate the percentage of patients whose tumours were deemed suitable for intraoperative mapping out of the total of patients referred to our neuro-oncology multi disciplinary team (MDT) - to identify causes of exclusion and/or failure of mapping Study design: prospective data collection over a period of 3 months METHODS: all patients seen in our neuro-oncology pre-assessment clinic were evaluated for the presence of tumours close to eloquent areas for movement or language, based on tumour location and clinical presentation. Inclusion criteria for patients selected for motor/speech mapping were: PS less than 2, absence of significant motor/language deficit at presentation and ability to tolerate awake surgery if required (especially for speech mapping). Follow up data on surgical complications were also collected. RESULTS: 58 patients were included in the 3 months study period. 37 patients had glioma, 9 metastasis, 8 meningioma, 4 other. 46 patients had a craniotomy, 12 a biopsy. Overall, 17 patients (29%) - all with diagnosis of glioma - had a tumour involving eloquent areas (10 motor, 7 language). Of these, 11 (19%) were operated with intraoperative mapping (7 motor, 4 language); 6 patients (10%) were not selected for mapping (2 due to inability to tolerate awake surgery, 2 poor PS, 2 had biopsy only). In terms of complications, 1 patient who had motor mapping had a postoperative infection, 1 patient had a postoperative bleeding after craniotomy for meningioma. CONCLUSIONS: nearly 1 in 5 patients seen in our neuro-oncology clinic had intraoperative mapping for tumour located in eloquent areas. Considering the gliomas only, the percentage was even higher (30%). This information can help to plan the activity within the neuro-oncology department, with better allocation of resources and budget.
STPs will end purchaser-provider split in parts of England, says NHS chief
Authors: Gareth Iacobucci
Journal: BMJ (2017)

The split between purchasers and providers of healthcare that has existed in the English NHS since 1990 will “effectively end” in parts of the country with the development of new accountable care organisations, the chief executive of NHS England has said.

Appearing before the House of Commons Public Accounts Committee on 27 February,1 Simon Stevens told MPs that some of the new models of integrated care being developed through sustainability and transformation plans (STPs) would dissolve …
Levels of GP-Iib/Iiia Positive Platelet Microparticles (PMP) but Not CD31+/CD42+ PMP Predict Adverse Outcomes in Troponin-Negative Patients with Chest Pain.
Authors: Julio A. Chirinos, Hermes Velazquez, Mariana Canoniero, Andres O. Soriano, Leon Bernal-Mizrachi, Wenche Jy, Lawrence L. Horstman, Joaquin J. Jimenez, Eduardo De Marchena, Alex Ferreira, Yeon S. Ahn
Journal: Blood (2004)
Abstract B21: PDE10A overexpression in colon cancer cells and tumors relative to normal colonocytes and colon mucosa
Authors: Ashley S. Lindsey, Kevin Lee, Joel Andrews, Wen-Chi L. Chang, Veronica Ramirez-Alcantara, Marcus Tan, William Grizzle, Margie L. Clapper, Gary Piazza
Journal: Cancer Research (2017)

Abstract Phosphodiesterase 10A (PDE10A) is a cGMP and cAMP degrading PDE isozyme expressed in areas of the brain controlling motor function and cognition. PDE10A has been strongly linked to diseases such as schizophrenia and Huntington's disease, for which PDE10A inhibitors are currently in clinical trials and appear to be well tolerated. Although, PDE10A has limited expression and no known function in peripheral tissues, high levels were measured in colon tumor cells in vitro and in vivo compared with cells derived from normal colon and colonic mucosa (Li et al., Oncogene 2015). PDE10A inhibition by small molecules or genetic silencing attenuated colon tumor cell growth by a mechanism involving cGMP/PKG activation, the suppression of oncogenic β-catenin, and a decrease in TCF transcriptional activity (Li et al., Oncogene 2015). These observations suggest that PDE10A may play an unrecognized role in tumorigenesis and provide a novel therapeutic target for colorectal cancer chemoprevention or therapy. The human colon tumor cell lines, HCT116, HT29, Caco2, and SW480, show elevated expression of PDE10A as compared to the normal colon mucosal epithelial cell line, NCM460, and are more sensitive to PDE10 inhibitors relative to NCM460 cells. Subcutaneous tumors established from HT29 colon tumor cells in athymic mice expressed elevated levels of PDE10A as compared to normal mouse colon tissue. Colon tumors collected from heterozygous APCmin/+FCCC mice displayed an elevation in PDE10A levels as compared to uninvolved mucosa from the APCmin/+FCCC mice and wild type colon mucosa. Overexpression of PDE10A mRNA and protein levels was also observed in colon adenocarcinomas relative to uninvolved colon mucosa in specimens obtained from colorectal cancer patients. These observations, along with recent findings that a novel sulindac derivative (ADT-061) with PDE10A inhibitory activity suppresses tumor formation in the APCmin/+FCCC mouse model of colon cancer without apparent toxicity, suggests that PDE10A provides a novel therapeutic target for cancer cell specific inhibition of tumor growth. Citation Format: Ashley S. Lindsey, Kevin Lee, Joel Andrews, Wen-Chi L. Chang, Veronica Ramirez-Alcantara, Marcus Tan, William Grizzle, Margie L. Clapper, Gary Piazza. PDE10A overexpression in colon cancer cells and tumors relative to normal colonocytes and colon mucosa. [abstract]. In: Proceedings of the AACR Special Conference on Colorectal Cancer: From Initiation to Outcomes; 2016 Sep 17-20; Tampa, FL. Philadelphia (PA): AACR; Cancer Res 2017;77(3 Suppl):Abstract nr B21.
Identification of Chitotriosidase Isoforms in Plasma of Gaucher Disease Patients by Two Dimensional Gel Electrophoresis.
Authors: Lucia Quintana, Alberto Monasterio, Kepa Escuredo, Jokin del Amo, Pilar Alfonso, Félix Elortza, Simon Santacruz, Laureano Simon, Antonio Martinez, Miguel Pocovi, Jose L. Castrillo, Pilar Giraldo
Journal: Blood (2005)
Predictors of Outcome In Adult Patients with Acute Myeloid Leukemia In First Relapse,
Authors: Farhad Ravandi, Stefan Faderl, Sherry Pierce, Guillermo Garcia-Manero, Mark Brandt, Jianqin Shan, Tapan Kadia, Gautam Borthakur, Zeev Estrov, Susan o'Brien, Jorge E. Cortes, Hagop M. Kantarjian
Journal: Blood (2011)
The Microbiome and Host Behavior
Authors: Helen E. Vuong, Jessica M. Yano, Thomas C. Fung, Elaine Y. Hsiao
Journal: Annual Review of Neuroscience (2017)

The microbiota is increasingly recognized for its ability to influence the development and function of the nervous system and several complex host behaviors. In this review, we discuss emerging roles for the gut microbiota in modulating host social and communicative behavior, stressor-induced behavior, and performance in learning and memory tasks. We summarize effects of the microbiota on host neurophysiology, including brain microstructure, gene expression, and neurochemical metabolism across regions of the amygdala, hippocampus, frontal cortex, and hypothalamus. We further assess evidence linking dysbiosis of the gut microbiota to neurobehavioral diseases, such as autism spectrum disorder and major depression, drawing upon findings from animal models and human trials. Finally, based on increasing associations between the microbiota, neurophysiology, and behavior, we consider whether investigating mechanisms underlying the microbiota-gut-brain axis could lead to novel approaches for treating particular neurological conditions.
Efficacy and Safety of Dasatinib in Patients with Chronic Myeloid Leukemia in Blast Phase Whose Disease Is Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from the START Program.
Authors: Carlo Gambacorti, Jorge Cortes, Dong-Wook Kim, Herve Dombret, Chao Zhu, Jan M.A. Van Tornout, Felix T. Garzon, Michele Baccarani
Journal: Blood (2007)
Lymphoma Cell Detection and Follow-Up in the Rituximab Era: Concordance between Flow Cytometry, Qualitative/Quantitative PCR and FISH in the Marrow and Blood from 647 Patients.
Authors: Patrizia Mancuso, Elisabetta Muratori, Cristina Rabascio, Angelica Calleri, Chiara Corsini, Francesco Bertolini
Journal: Blood (2004)
Influence of expression of EGFR and PTEN on outcome in patients with primary glioblastoma treated with standard radiochemotherapy and cetuximab: Interim analysis from the GERT-Protocol
Authors: S. E. Combs, C. Hartmann, J. Welzel, A. von Deimling, J. Debus, M. Platten, W. Wick, T. Gaiser
Journal: Journal of Clinical Oncology (2009)

2050 Background: The epidermal growth factor receptor (EGFR) is commonly amplified, overexpressed, and mutated in glioblastoma (GBM). Anti-EGFR treatments have shown to be associated with EGFR deletion mutant variant III (EGFRvIII) expression in presence of PTEN expression, suggesting a prognostic role of EGFRvIII expression. We determined molecular biomarkers and correlated these with outcome in the GERT trial. Methods: To date, 39 patients were treated within the GERT protocol (Combs SE et al., 2006) evaluating radiochemotherapy (RCHT) with temozolomide (TMZ) and weekly CTX. Pretreatment paraffin-embedded tumor tissue of 32 patients was available for molecular analysis. Twenty-three patients were male, 9 were female. Median age was 49 years. We analyzed amplification of EGFR, expression of EGFR, EGFRvIII, the tumor-suppressor PTEN and O(6)-methylguanine DNA methyltransferase (MGMT) gene promoter methylation. Results: Median follow-up was 12 months. Overall survival (OS) at 12 and 24 months was 89% and 42%. Progression-free survival (PFS) was 76% and 45% at 6 and 12 months, respectively. MGMT promoter hypermethylation was detected in 16/32 tumours. Methylated MGMT did not impact PFS or OS (p = 0.48 and p = 0.08). Data on EGFR copy number of 31/32 tumors showed EGFR gene amplification in 11 tumors. EGFR protein expression was found in 23/32 patients. EGFR-amplification did not impact PFS or OS (p = 0.56, p = 0.3). Patients with EGFR expression showed longer PFS (p = 0.05), but unaltered OS (p = 0.06). EGFRvIII was seen in 5/32 patients, only in tumors with EGFR amplification. Expression of EGFRvIII did not influence PFS (p = 0.26) or OS (p = 0.09). Reduced PTEN (22/32) did not influence PFS or OS (p = 0.27, p = 0.85). Outcome was not associated with coexpression of EGFRvIII and PTEN (n = 5); coexpression of EGFR and PTEN (n = 13) significantly influenced PFS (p = 0.005), but not OS (p = 0.10). Conclusions: Expression of EGFR, and coexpression of EGFR/PTEN is associated with significant increase in PFS after RCHT with TMZ and CTX. EGFR-amplification, reduction of PTEN expression and expression of EGFRvIII did not impact PFS nor OS. Randomized data in the primary treatment of GBM might help identify patients for anti-EGFR therapies. [Table: see text]
Potential of Oncocardiology
Authors: Jennifer Cautela, Nathalie Lalevee, Franck Thuny
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination with Fludarabine and Cytarabine in Pediatric Patients with Relapsed or Refractory AML
Authors: Jeffrey E Rubnitz, Ronda Kaufman, Raul C. Ribeiro, Boris Klebanov, Joel Ellis, Yosef Landesman, Hagop Youssoufian, Tami Rashal, Sharon Shacham
Journal: Blood (2015)
Abstract P2-10-05: PowerPIINC trial: Changes in tumor proliferation index and quality of life with 7 days of preoperative tamoxifen
Authors: AL Cohen, RE Factor, K Mooney, M Wade, V Serpico, M Salama, E Nelson, J Porretta, C Matsen, E Ostrander, P Bernard, K Boucher, L Neumayer
Journal: Cancer Research (2017)

Abstract BACKGROUND: A decrease in Ki67 has been shown to be a predictor of response to tamoxifen. Previous trials have shown a decreased Ki67 proliferation index in breast tumors with as little as 2 weeks of preoperative tamoxifen. However, shortening the preoperative treatment time in window of opportunity studies increases patient acceptance for trial participation. The POWERPIINC trial examined the effect of 7 days of preoperative tamoxifen on breast tumor proliferation and patient symptoms. METHODS: Adult women with untreated stage I or II invasive breast cancer that was ER positive (&amp;gt;1%) planning on breast surgery with no contraindications to tamoxifen were enrolled. Women received 20mg of tamoxifen for 7 days up to the day of surgery and for 14 days afterwards. Proliferation was assessed by Ki67 immunohistochemistry before and after 7 days of tamoxifen. The proliferation genes from the PAM50 were also assessed by RT-PCR. Symptoms and QOL were assessed by the FACT-ES, MENQoL, and BMQ. RESULTS: 52 women were enrolled, and 44 were evaluable for Ki67. The median age was 58.5 years, and the median tumor diameter was 1.2cm. Most women (73%) were post-menopausal. Most tumors were PR positive (88%). Only 8% of tumors were HER2-positive. The Ki67 decreased by a geometric mean of 40% (95% CI 29%-63%), and 73% (95% CI 57%-85%) of women had tumors with decreased proliferation after 7 days of tamoxifen (p=0.0001 by paired t-test). No correlation was seen between the change in Ki-67 and change in FACT-ES or MENQoL scores. Women reported minimal to no bother from psychosocial or physical symptoms at baseline or on the day of surgery. Expression level of individual proliferation genes did not change after 7 days of tamoxifen. CONCLUSION: Seven days of tamoxifen showed a similar relative decrease in the Ki67 proliferation index as that reported for longer courses. Therefore, short window of opportunity trials can be informative. Citation Format: Cohen AL, Factor RE, Mooney K, Wade M, Serpico V, Salama M, Nelson E, Porretta J, Matsen C, Ostrander E, Bernard P, Boucher K, Neumayer L. PowerPIINC trial: Changes in tumor proliferation index and quality of life with 7 days of preoperative tamoxifen [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-10-05.
Uncovering the roles of long non-coding RNAs in cancer stem cells
Authors: Xiaoxing Huang, Ruijing Xiao, Shan Pan, Xiangyong Yang, Wen Yuan, Zhenbo Tu, Ming Xu, Yufan Zhu, Qian Yin, Yingjie Wu, Weidong Hu, Liang Shao, Jie Xiong, Qiuping Zhang
Journal: Journal of Hematology & Oncology (2017)

Cancer has been a major public health problem that has threatened human life worldwide throughout history. The main causes that contribute to the poor prognosis of cancer are metastasis and recurrence. Cancer stem cells are a group of tumor cells that possess self-renewal and differentiation ability, which is a vital cause of cancer metastasis and recurrence. Long non-coding RNAs refer to a class of RNAs that are longer than 200 nt and have no potential to code proteins, some of which can be specifically expressed in different tissues and different tumors. Long non-coding RNAs have great biological significance in the occurrence and progression of cancers. However, how long non-coding RNAs interact with cancer stem cells and then affect cancer metastasis and recurrence is not yet clear. Therefore, this review aims to summarize recent studies that focus on how long non-coding RNAs impact tumor occurrence and progression by affecting cancer stem cell self-renewal and differentiation in liver cancer, prostate cancer, breast cancer, and glioma.
Abstract B06: Circulatory shear flow alters the viability and proliferation of circulating colon cancer cells
Authors: Fan Rong, Travis Emery, Yongguo Zhang, Yuxuan Xia, Jun Sun, Jiandi Wan
Journal: Cancer Research (2017)

Abstract During cancer metastasis, circulating tumor cells constantly experience hemodynamic shear stress in the circulation. Cellular responses to shear stress including cell viability and proliferation thus play critical roles in cancer metastasis. Here, we developed a microfluidic approach to establish a physiologically relevant circulatory microenvironment and studied circulating human colon cancer HCT116 cells in response to a variety of magnitude of shear stress and circulating time. Our results showed that cell viability decreased with the increase of circulating time, but increased with the magnitude of shear stress. Proliferation of cells survived from circulation could be maintained when physiologically relevant shear stresses were applied. High shear stress (60.5 dyne/cm2), however, led to decreased cell proliferation at long circulating time (1 h). We further showed that the expression levels of β-catenin and c-myc, proliferation regulators, were significantly enhanced by increasing shear stress. These data provided molecular based explanation for the observed cell viability at high shear. The presented study provides a new insight to the roles of circulatory shear stress in cellular responses of circulating tumor cells in a physiologically relevant model, and thus will be of interest for the study of cancer cell mechanosensing and cancer metastasis. Citation Format: Fan Rong, Travis Emery, Yongguo Zhang, Yuxuan Xia, Jun Sun, Jiandi Wan. Circulatory shear flow alters the viability and proliferation of circulating colon cancer cells. [abstract]. In: Proceedings of the AACR Special Conference on Engineering and Physical Sciences in Oncology; 2016 Jun 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2017;77(2 Suppl):Abstract nr B06.
Molecular Basis of Ibrutinib Resistance in Waldenstrom's Macroglobulinemia
Authors: Lian Xu, Nicholas Tsakmaklis, Guang Yang, Jiaji G Chen, Xia Liu, Jie Chen, Maria Demos, Christopher J Patterson, Toni Dubeau, Kirsten Meid, Joshua Gustine, Jorge J. Castillo, Ranjana H Advani, Maria Lia Palomba, Richard R. Furman, Zachary Hunter, Steven P Treon
Journal: Blood (2016)
Older Age Increases Non-Relapse Mortality in Patients with Grade II–IV Acute Gvhd After Allogeneic Hematopoietic Cell Transplantation: A Retrospective Analysis of the Japanese Trump Database.
Authors: Takahiko Nakane, Takahiro Fukuda, Junya Kanda, Shuichi Taniguchi, Tetsuya Eto, Kazuteru Ohashi, Yasuo Morishima, Tokiko Nagamura, Hisashi Sakamaki, Yoshiko Atsuta, Makoto Murata
Journal: Blood (2012)
Evidence for the Baby-Friendly Hospital Initiative to Support Breastfeeding
Authors: Melissa C. Bartick, Nathan C. Nickel, Lauren E. Hanley
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Self-Efficacy as a Measure of Confidence—Reply
Authors: Dawn M. Elfenbein
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Safety and Preliminary Efficacy of Recombinant Activated FVII Analog (NN1731) In the Treatment of Joint Bleeds In Congenital Hemophilia Patients with Inhibitors
Authors: Erich de Paula, Kaan Kavakli, Johnny Mahlangu, Yasmin Ayob, Steven R. Lentz, Massimo Morfini, László Nemes, Silva Zupancic Salek, Midori Shima, Jerzy Windyga, Silke Ehrenforth, Henning Friis Andersen, Ampaiwan Chuansumrit
Journal: Blood (2010)
Survey of European lung cancer evaluating choice of treatment and tolerability in observed 2nd line NSCLC (SELECTTION): cluster analysis of baseline results
Authors: D. Moro-Sibilot, A. Vergnenegre, E. F. Smit, E. Toy, B. Parente, S. Schmitz, Kaisa Taipale, Victoria Soldatenkova, Claudia Leteneux, Kees Kraaij
Journal: Journal of Thoracic Oncology (2009)